Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 V514L |
| Therapy | Fexagratinib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 V514L | lung non-small cell carcinoma | no benefit | Fexagratinib | Case Reports/Case Series | Actionable | In a Phase II trial (NLMT), Fexagratinib (AZD4547) treatment did not result in a confirmed response or durable clinical benefit in a patient with non-small cell lung cancer harboring FGFR2 V515L (corresponds to V514L in the canonical isoform (PMID: 32669708, NCT02664935). | 32669708 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32669708) | The National Lung Matrix Trial of personalized therapy in lung cancer. | Full reference... |